Recent Updates
Recently added Catalysts
ANNX Positive Sentiment

Annexon Appoints Renowned Retinal Surgeon and Biotechnology Entrepreneur Mark S. Blumenkranz, M.D., M.M.S. to its Board of Directors

Monday, August 10, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Annexon, Inc. has appointed Dr. Mark S. Blumenkranz to its Board of Directors. With over 40 years of experience in clinical, scientific, and corporate leadership, Dr. Blumenkranz is expected to drive innovation in the field of retinal disease. This strategic move aims to strengthen Annexon's position in advancing targeted immunotherapies.

Market Sentiment Analysis

POSITIVE FACTORS

  • Appointment of a renowned expert enhances leadership team.
  • Dr. Blumenkranz brings over four decades of experience.
  • Focus on innovation in retinal disease treatment.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+28%
120-day peak, hindsight
Typical move
5.3%
average across 5 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
ANX005
Phase 3 · Guillain-Barre Syndrome

Full Press Release Details

Over Four Decades of Clinical, Scientific and Corporate Leadership Advancing Innovation in Retinal Disease BRISBANE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple

Frequently Asked Questions

Who is Dr. Mark S. Blumenkranz?

Dr. Mark S. Blumenkranz is a renowned retinal surgeon and biotechnology entrepreneur.

What is the significance of Dr. Blumenkranz's appointment?

His appointment strengthens Annexon's leadership in advancing retinal disease treatments.

How many years of experience does Dr. Blumenkranz have?

Dr. Blumenkranz has over four decades of experience in clinical and corporate leadership.

What is Annexon focused on?

Annexon is focused on developing targeted immunotherapies for retinal diseases.

ShareAdd on Google
Tags: ANNX Viatris Investor Conferences Healthcare Annexon Mark Blumenkranz retinal disease biopharmaceutical immunotherapies
Last updated: Aug 10, 2026

Biotech snapshot

Cash runway
$225M liquidity · $16M/mo burn
~11 mo
Medium dilution risk
Lead asset
ANX005Phase 3
Guillain-Barre Syndrome →

Catalyst track record

+28%
best trade around ANNX's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for ANNX.

See every catalyst's timing & PoA →